TVGN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
5.7M
+4.8%
5.4M
+17.2%
4.6M
-19.5%
5.7M
+5.2%
5.4M
R&D
3.3M
+4.7%
3.1M
+48.9%
2.1M
-32.3%
3.1M
+15.2%
2.7M
SG&A
2.4M
+5.0%
2.3M
-9.5%
2.5M
-4.4%
2.6M
-4.6%
2.7M
Operating Income
-5662376
-4.8%
-5400920
-17.2%
-4610201
+19.5%
-5729431
-5.2%
-5444536
EBITDA
-5632108
-4.9%
-5370652
-26.9%
-4233516
+26.1%
-5728913
-7.0%
-5353095
Net Income
-5761940
-5.8%
-5446255
-16.4%
-4677580
+18.3%
-5726812
-4.0%
-5503979
EPS (Basic)
$-1.52
+5.6%
$-1.61
$-1.50
+12.3%
$-1.71
EPS (Diluted)
$-1.52
+5.6%
$-1.61
$-1.50
+12.3%
$-1.71
Shares (Diluted)
3.8M
+9.8%
3.5M
3.9M
+19.1%
3.3M
Tevogen (TVGN) — Financials